Should You Buy Cingulate Inc (CING) Stock on Thursday?

Overall market sentiment has been down on Cingulate Inc (CING) stock lately. CING receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Cingulate Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on CING!

See Full CING Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With CING Stock Today?

Cingulate Inc (CING) stock is trading at $1.11 as of 2:54 PM on Thursday, Mar 28, an increase of $0.02, or 1.83% from the previous closing price of $1.09. The stock has traded between $1.08 and $1.12 so far today. Volume today is below average. So far 64,117 shares have traded compared to average volume of 256,565 shares. To see InvestorsObserver's Sentiment Score for Cingulate Inc click here.

More About Cingulate Inc

Cingulate Inc is a clinical stage biopharmaceutical company utilizing its proprietary precision timed release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. Click Here to get the full Stock Report for Cingulate Inc stock.